Search / Trial NCT06233071

Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®

Launched by BIO-INNOVA CO., LTD · Jan 22, 2024

Apply for Trial

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Drospirenone (3 Mg) + Ethinyl Estradiol (0.02 Mg) Tablets

Description

Title A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets relative to Yaz® in healthy Thai female volunteers under fasting condition. Objectives The primary objective is to compare the rate and extent of absorption of a generic formulation with that of a reference formulation when given as equal labeled dose. The secondary objective is to evaluate the safety after oral administration of both test and reference formulation in healthy Thai female ...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Willingness to provide written informed consent prior to participate in the study.
  • 2. Healthy Thai female subjects are between 18 to 55 years of age.
  • 3. The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
  • 4. Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects' safety after the completion of the study.
  • 5. Negative urine pregnancy test and no breast-feeding.
  • 6. Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
  • Exclusion Criteria:
  • 1. History or evidence of allergy or hypersensitivity to Drospirenone or Ethinyl Estradiol or any related drugs or any of the excipients of this product.
  • 2. Subject with B.P. is Systolic B.P \<90, ≥140 mm/Hg, Diastolic B.P \<60, ≥90 mm/Hg, pulse rate \>100 beats per minute.
  • 3. Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).\*
  • 4. Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).\*
  • 5. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).\*
  • 6. Positive of hepatitis B or C virus.
  • 7. Have more than one abnormal EKG, which is considered as clinically significant. \*
  • 8. History or evidence of heart (heart attack, angina pectoris), renal, hepatic disease, adrenal insufficiency, pulmonary obstructive disease, bronchial asthma, hypertension, vascular disease (deep vein thrombosis, pulmonary embolism, venous thromboembolism, stroke, transient ischemic attack), migraine with aura, metabolic disorder, or glaucoma
  • 9. History or Family history of VTE in a first degree relative under the age of 45.
  • 10. History of abnormal vaginal bleeding or coagulopathy.
  • 11. History or Family history in a first degree of breast cancer.
  • 12. History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
  • 13. Any major illness in the past 3 months or any significant ongoing chronic medical illness.
  • 14. History of psychiatric disorder or depression.
  • 15. History of regular alcohol consumption exceeding 7 drinks/week for females (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
  • 16. History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of each period of the study.
  • 17. High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
  • 18. History of pomelo or grapefruit or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of each period of the study.
  • 19. History of St. John's Wort products consumption and cannot stop at least 28 days before the study drug administration and until the completion of the study.
  • 20. Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
  • 21. Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication.
  • 22. History of difficulty in accessibility of veins in left and right arm.
  • 23. Blood donation (one unit or 450 mL) within the past 3 months before the study.
  • 24. Participation in any clinical study within the past 3 months before the study.
  • 25. Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
  • (\* Depend on decision of principal investigator and/or clinical investigator)

About Bio Innova Co., Ltd

Bio-Innova Co., Ltd. is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a focus on enhancing patient outcomes, the company specializes in conducting high-quality clinical trials across various therapeutic areas. Bio-Innova is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and efficacy of its investigational products. Through collaboration with healthcare professionals and research institutions, Bio-Innova aims to accelerate the delivery of groundbreaking therapies to the market, ultimately improving the quality of life for patients worldwide.

Locations

Bangkok, , Thailand

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0